Neurogene Valuation
| NGNE Stock | 20.60 1.51 6.83% |
At this time, the firm appears to be fairly valued. Neurogene secures a last-minute Real Value of USD19.89 per share. The latest price of the firm is USD20.6. Our model forecasts the value of Neurogene from analyzing the firm fundamentals such as Current Valuation of 64.95 M, shares owned by insiders of 8.54 %, and Return On Equity of -0.42 as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Neurogene's price fluctuation is somewhat reliable at this time. Calculation of the real value of Neurogene is based on 3 months time horizon. Increasing Neurogene's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Neurogene stock is determined by what a typical buyer is willing to pay for full or partial control of Neurogene. Since Neurogene is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Neurogene Stock. However, Neurogene's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 20.6 | Real 19.89 | Hype 20.6 | Naive 19.96 |
The real value of Neurogene Stock, also known as its intrinsic value, is the underlying worth of Neurogene Company, which is reflected in its stock price. It is based on Neurogene's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Neurogene's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Neurogene helps investors to forecast how Neurogene stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Neurogene more accurately as focusing exclusively on Neurogene's fundamentals will not take into account other important factors: Neurogene Total Value Analysis
Neurogene is now estimated to have valuation of 64.95 M with market capitalization of 319.09 M, debt of 12.43 M, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Neurogene fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
64.95 M | 319.09 M | 12.43 M |
Neurogene Investor Information
About 91.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.1. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Neurogene recorded a loss per share of 4.1. The entity had not issued any dividends in recent years. The firm had 1:4 split on the 19th of December 2023. Based on the measurements of operating efficiency obtained from Neurogene's historical financial statements, Neurogene is not in a good financial situation at the moment. It has a very high risk of going through financial straits in February.Neurogene Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Neurogene has an asset utilization ratio of 0.28 percent. This indicates that the Company is making USD0.002755 for each dollar of assets. An increasing asset utilization means that Neurogene is more efficient with each dollar of assets it utilizes for everyday operations.Neurogene Ownership Allocation
The majority of Neurogene outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Neurogene to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Neurogene. Please pay attention to any change in the institutional holdings of Neurogene as this could imply that something significant has changed or is about to change at the company.Neurogene Profitability Analysis
The company reported the previous year's revenue of 925 K. Net Loss for the year was (75.14 M) with loss before overhead, payroll, taxes, and interest of (69.72 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Neurogene's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Neurogene and how it compares across the competition.
About Neurogene Valuation
The stock valuation mechanism determines Neurogene's current worth on a weekly basis. Our valuation model uses a comparative analysis of Neurogene. We calculate exposure to Neurogene's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Neurogene's related companies.Complementary Tools for Neurogene Stock analysis
When running Neurogene's price analysis, check to measure Neurogene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurogene is operating at the current time. Most of Neurogene's value examination focuses on studying past and present price action to predict the probability of Neurogene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurogene's price. Additionally, you may evaluate how the addition of Neurogene to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |